Soluble P-selectin level correlates with acetylsalicylic acid but not with clopidogrel response in patients with stable coronary artery disease after a percutaneous coronary intervention

Coronary Artery Disease

Volumn 24, Issue 4, 2013, Pages 312-320

  Kaufmann, Jan ^a   Wellnhofer, Ernst ^a   Kappert, Kai ^b   Urban, Daniel ^a   Meyborg, Heike ^a   Hauptmann, Tobias ^a   Müller, Aline ^a   Meixner, Martin ^c   Graf, Kristof ^a,d   Fleck, Eckart ^a   Stawowy, Philipp ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d Jewish Hospital Berlin   (Germany)

Author keywords

CYP2C19*2 genotype; Dual antiplatelet therapy; Inflammatory markers; Platelet function

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CD40 LIGAND; CLOPIDOGREL; COLLAGEN; CYTOCHROME P450 2C19; PADGEM PROTEIN; PHOSPHOPROTEIN; SOLUBLE CD40 LIGAND; SOLUBLE P SELECTIN; UNCLASSIFIED DRUG; VASODILATOR AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATIONAL STUDY; DRUG ABSORPTION; DRUG METABOLISM; DRUG RESPONSE; FEMALE; GENETIC VARIABILITY; HEART EJECTION FRACTION; HETEROZYGOTE; HUMAN; LIGHT TRANSMITTANCE AGGREGOMETRY; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DEPHOSPHORYLATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

AGED; ANTI-INFLAMMATORY AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; CD40 LIGAND; CELL ADHESION MOLECULES; CORONARY ARTERY DISEASE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; P-SELECTIN; PERCUTANEOUS CORONARY INTERVENTION; PHOSPHOPROTEINS; PLATELET AGGREGATION INHIBITORS; STENTS; TICLOPIDINE;

EID: 84877010759     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328360efd3     Document Type: Article

References (45)

1. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527-533.
2. Geisler T, Langer H, Wydymus M, Go hring K, Zu rn C, Bigalke B, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27:2420-2425.
3. Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 6:54-61.
4. Sibbing D, von Beckerath O, Scho mig A, Kastrati A, von Beckerath N. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007; 100:203-205.
5. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108:2244-2247.
6. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et al. Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51:1925-1934.
7. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80:486-501.
8. Lau WC, Gurbel PA. Antiplatelet drug resistance and drug-drug interactions: role of cytochrome P450 3A4. Pharm Res 2006; 23:2691-2708.
9. Patel D, Moonis M. Clinical implications of aspirin resistance. Expert Rev Cardiovasc Ther 2007; 5:969-975.
10. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51:1829-1843.
11. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115:3378-3384.
12. Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost 2010; 103:71-82.
13. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106:1523-1529.
14. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003; 108:1049-1052.
15. Henn V, Slupsky JR, Gra fe M, Anagnostopoulos I, Fo rster R, Mu ller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391:591-594.
16. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54:669-677.
17. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348:1104-1111.
18. Aukrust P, Damas JK, Solum NO. Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation? J Am Coll Cardiol 2004; 43:2326-2328.
19. Cipollone F, Ferri C, Desideri G, Paloscia L, Materazzo G, Mascellanti M, et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 2003; 108:2776-2782.
20. Dunlop LC, Skinner MP, Bendall LJ, Favaloro EJ, Castaldi PA, Gorman JJ, et al. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med 1992; 175:1147-1150.
21. McEver RP. Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. Blood Cells 1990; 16:73-80, discussion 80-73.
22. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24:2166-2179.
23. Blann AD, Lip GY, Beevers DG, McCollum CN. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost 1997; 77:1077-1080.
24. Ferroni P, Martini F, Riondino S, La Farina F, Magnapera A, Ciatti F, et al. Soluble P-selectin as a marker of in vivo platelet activation. Clin Chim Acta 2009; 399:88-91.
25. Quinn MJ, Bhatt DL, Zidar F, Vivekananthan D, Chew DP, Ellis SG, et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004; 93:679-684.
26. Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004; 43:1982-1988.
27. Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Lu scher TF. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007; 12:113-122.
28. Chirumamilla AP, Maehara A, Mintz GS, Mehran R, Kanwal S,Weisz G, et al. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovasc Imaging 2012; 5:540-549.
29. Dav? G, Romano M, Mezzetti A, Procopio A, Iacobelli S, Antidormi T, et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998; 97:953-957.
30. Vora DK, Fang ZT, Liva SM, Tyner TR, Parhami F,Watson AD, et al. Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression. Circ Res 1997; 80:810-818.
31. Kirk G, McLaren M, Muir AH, Stonebridge PA, Belch JJ. Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment. Vasc Med 1999; 4:23-26.
32. Romano M, Mezzetti A, Marulli C, Ciabattoni G, Febo F, Di Ienno S, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med 2000; 48:183-189.
33. Wenaweser P, Do rffler-Melly J, Imboden K,Windecker S, Togni M, Meier B, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005; 45:1748-1752.
34. Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 2003; 73:232-241.
35. Varughese GI, Patel JV, Tomson J, Blann AD, Hughes EA, Lip GY. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial. J Intern Med 2007; 261:384-391.
36. Yip HK, Chang LT, Sun CK, Yang CH, Hung WC, Cheng CI, et al. Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting. Am J Cardiol 2006; 97:192-194.
37. Obradovic SD, Antovic JP, Antonijevic NM, Ratkovic NG, Vojvodic DV, Subota VS, et al. Elevations in soluble CD40 ligand in patients with high platelet aggregability undergoing percutaneous coronary intervention. Blood Coagul Fibrinolysis 2009; 20:283-289.
38. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001; 89:1092-1103.
39. Tousoulis D, Antoniades C, Nikolopoulou A, Koniari K,Vasiliadou C, Marinou K, et al. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur J Clin Invest 2007; 37:623-628.
40. Aukrust P, Mu ller F, Ueland T, Berget T, Aaser E, Brunsvig A, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100:614-620.
41. Peng DQ, Zhao SP, Li YF, Li J, Zhou HN. Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome. Clin Chim Acta 2002; 319:19-26.
42. Yngen M, Ostenson CG, Hu H, Li N, Hjemdahl P,Wallen NH. Enhanced Pselectin expression and increased soluble CD40 ligand in patients with type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia 2004; 47:537-540.
43. Sakurai S, Inoue A, Koh CS, Owa M, Yanagisawa N. Soluble form of selectins in blood of patients with acute myocardial infarction and coronary intervention. Vasc Med 1997; 2:163-168.
44. Xu DY, Zhao SP, Peng WP. Elevated plasma levels of soluble P-selectin in patients with acute myocardial infarction and unstable angina. An inverse link to lipoprotein(a). Int J Cardiol 1998; 64:253-258.
45. Viles-Gonzalez JF, Fuster V, Corti R, Valdiviezo C, Hutter R, Corda S, et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition-a magnetic resonance imaging study. Eur Heart J 2005; 26:1557-1561.